MAP2K7 and neoplasm: Sorafenib and sunitinib are among RTKIs that block angiogenesis and tumor growth via targeting the RAF/MEK/ERK signaling pathway, VEGFR-2, PDGFRB, and colony-stimulating factor-1 (CSF-1) [43,44].